| Field | Specification |
|---|---|
| Target | |
| Alternative names | Mitogen-activated protein kinase 9;MAP kinase 9;MAPK 9;2.7.11.24;JNK-55;Stress-activated protein kinase 1a;SAPK1a;Stress-activated protein kinase JNK2;c-Jun N-terminal kinase 2;MAPK9;JNK2, PRKM9, SAPK1A; |
| UniProt # | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthesized peptide derived from human JNK2 |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Liquid |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Clone EIF-13 is a rabbit monoclonal antibody that recognizes mitogen-activated protein kinase 9 (gene MAPK9) in human, monkey, mouse and rat samples and is validated for Western blot, IHC, ICC/IF, immunoprecipitation and flow cytometry. The predicted molecular weight is 48.1 kDa, and the supplier reports an observed band at about 48 kDa.
JNK2 (MAPK9) is a close relative of JNK1 in the c-Jun N-terminal kinase branch of MAP kinase signaling. Activated by inflammatory cytokines and cellular stress, it phosphorylates c-Jun and other transcription factors to shape gene expression, and it often shares or balances roles with JNK1 in cell death, immune responses and stress adaptation.
| Target | Mitogen-activated protein kinase 9 (gene MAPK9; UniProt P45984, human) |
|---|---|
| Clone | EIF-13 |
| Host / Clonality / Isotype | Rabbit / Monoclonal / Rabbit IgG |
| Reactivity | Human, Monkey, Mouse, Rat |
| Form | Liquid |
| Formulation | PBS (pH 7.4); 150 mM NaCl; 0.02% sodium azide; 50% glycerol; plus stabilizers |
| Calculated MW | 48.1 kDa |
| Observed MW | 48 kDa |
| Storage | Long term: −20 °C for up to 12 months. Frequent use: 4 °C for up to 1 month. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 1:500–1:2000 |
|---|---|
| Immunohistochemistry | 1:50–1:200 |
| Immunocytochemistry / Immunofluorescence | 1:50–1:200 |
| Immunoprecipitation | 1:20 |
| Flow cytometry | 1:20 |
Samples with a confirmed band (WB): human HeLa cells, human 293T cells, monkey COS-7 cells, rat brain tissue, rat liver tissue, mouse brain tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 1:500 overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): rat intestine tissue, human prostate cancer tissue, human astrocytoma tissue, mouse skin tissue, human colon tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Immunogen
Synthetic peptide based on the sequence of human JNK2.
Reactivity Notes
The supplier lists reactivity with human, monkey, mouse and rat. UniProt places mitogen-activated protein kinase 9 in the cytoplasm and nucleus. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Fengmei Song et al. (2017) Pseudolaric acid B inhibits neuroglioma cell proliferation through DNA damage response. Oncology Reports. 10.3892/or.2017.5861
